active CNS lesions on CT/MRI within 28 days prior to enrollment
history of spinal cord compression o carcinomatous meningitis
anticipated or ongoing anti-cancer therapies other than those administered in this study
previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor
severe cardiovascular disease within 6 months prior to study
previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix
